← Back to Clinical Trials
Recruiting NCT05481749

NCT05481749 Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05481749
Status Recruiting
Phase
Sponsor Consorci Sanitari de l'Alt Penedès i Garraf
Condition Dementia
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2023-02-14
Primary Completion 2026-03

Eligibility & Interventions

Sex All sexes
Min Age 80 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2023-02-14 with a primary completion date of 2026-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Neuropsychological tests currently considered to evaluate the cognitive performance of the oldest-old population (more than 80 years) are not adapted to this group population. This trial aims to determine the normal limits for this group population of a set of 18 neuropsychological test. Results may improve the diagnostic cognitive evaluation of this population.

Eligibility Criteria

Inclusion Criteria: * 80 or more years old * Residence at Comarca del Garraf * Able to be transfered to study center * Sufficient reading and writing capacity to carry out the neuropsychological tests, at the evaluator's discretion. Exclusion Criteria: * Patient at end-of-life situation or with a very short life expectancy (days-weeks). * Hospital admission in the previous 3 months. * History of relevant mental illness: major depression, psychosis, bipolar disorder, obsessive-compulsive disorder. * Disease of the central nervous system with possible cognitive impairment: Parkinson's disease, multiple sclerosis, brain tumor, stroke with cognitive impairment, epilepsy, severe traumatic brain injury. * History of alcoholism or substance abuse. * Severe sensory deficit that prevents performing neuropsychological tests, at the discretion of the evaluator. * Positive Shortened Spanish Informant Questionnaire for Cognitive Decline in the Elderly questionnaire (SS-IQCODE) or Lobo's Cognitive Mini-examination Test (spanish adaptation of Minimental of Folstein test) with a score \< 23 (20 in people with low schooling or illiteracy). * Dementia criteria according to the Diagnostic and Statistical Manual of Mental Disorders IV.

Contact & Investigator

Central Contact

César Gálvez-Barrón, Ph.D.

✉ cgalvez@csapg.cat

📞 0034 626419884

Principal Investigator

César Gálvez-Barrón, Ph.D.

PRINCIPAL INVESTIGATOR

Consorci Sanitari de l'Alt Penedès i Garraf

Frequently Asked Questions

Who can join the NCT05481749 clinical trial?

This trial is open to participants of all sexes, aged 80 Years or older, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05481749 currently recruiting?

Yes, NCT05481749 is actively recruiting participants. Contact the research team at cgalvez@csapg.cat for enrollment information.

Where is the NCT05481749 trial being conducted?

This trial is being conducted at Sant Pere de Ribes, Spain, Sitges, Spain, Vilanova i la Geltrú, Spain, Vilanova i la Geltrú, Spain and 2 additional locations.

Who is sponsoring the NCT05481749 clinical trial?

NCT05481749 is sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. The principal investigator is César Gálvez-Barrón, Ph.D. at Consorci Sanitari de l'Alt Penedès i Garraf. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology